533PDBACCI: A phase II randomized, double-blind,...

Annals of Oncology 2019 / 10 Vol. 30; Iss. Supplement

533PDBACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

Mettu, N B, Twohy, E, Ou, F-S, Halfdanarson, T R, Lenz, H J, Breakstone, R, Boland, P M, Crysler, O, Wu, C, Grothey, A, Nixon, A B, Bolch, E, Niedzwiecki, D, Fruth, B, Schweitzer, B, Elsing, A, Hurwit
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz246.011
Date:
October, 2019
File:
PDF, 80 KB
2019
Conversion to is in progress
Conversion to is failed